MDCXW
Medicus Pharma Ltd.
NasdaqCMUSDEQUITY
DELAYED
Last price
0.33
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.33
Day high
0.33
Day low
0.33
Volume
59
Market cap
—
P/E (TTM)
—
52W range
0.33 – 2.50
Free account
3 more panels on MDCXW open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $16.44M | $3.53M | $193.58K | $646.38K | +366.0% |
| Selling, general & admin | $17.92M | $7.65M | $2.46M | $332.03K | +134.2% |
| Total operating expense | $34.36M | $11.18M | $2.66M | $978.42K | +207.3% |
| Operating income | -$34.36M | -$11.18M | -$2.66M | -$978.42K | -207.3% |
| Net interest income | -$197.38K | $25.39K | -$584.82K | -$1.10M | -877.5% |
| Pre-tax income | -$35.44M | -$11.16M | -$5.31M | -$1.69M | -217.7% |
| Net income | -$35.44M | -$11.16M | -$5.31M | -$1.69M | -217.7% |
| Net income to common | -$47.28M | -$11.16M | -$5.31M | -$1.69M | -323.8% |
| EBIT | -$34.36M | -$11.18M | -$2.66M | -$1.17M | -207.3% |
| EBITDA | -$34.36M | -$11.18M | -$2.66M | -$1.17M | -207.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.71M | $4.16M | $1.72M | $267.65K | — | +109.0% |
| Cash & short-term investments | $8.71M | $4.16M | $1.72M | $267.65K | — | +109.0% |
| Total current assets | $9.89M | $5.38M | $1.89M | $282.65K | — | +83.9% |
| Property, plant & equipment | $170.73K | $268.57K | $0 | — | — | -36.4% |
| Total assets | $10.06M | $5.65M | $1.89M | $282.65K | — | +78.2% |
| Total current liabilities | $9.94M | $2.31M | $781.61K | $12.48M | — | +330.9% |
| Current debt | $5.25M | — | — | $1.53M | $667.93K | — |
| Long-term debt | $25.86K | — | — | — | — | — |
| Total debt | $5.48M | $322.27K | $0 | $1.53M | — | +1,599.5% |
| Total liabilities | $10.02M | $2.51M | $781.61K | $12.48M | — | +299.0% |
| Retained earnings | -$64.35M | -$28.90M | -$17.75M | -$12.39M | — | -122.6% |
| Shareholder equity | -$67.55K | $3.13M | $1.11M | -$12.20M | — | -102.2% |
| Working capital | -$47.42K | $3.07M | $1.11M | -$12.20M | — | -101.5% |
| Net tangible assets | -$67.55K | $3.13M | $1.11M | -$12.20M | — | -102.2% |
| Shares issued | 25.18M | 11.82M | 8.08M | 8.05M | — | +113.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$35.44M | -$11.16M | -$5.31M | -$1.69M | -217.7% |
| Stock-based compensation | $1.51M | $713.12K | $98.58K | $0 | +112.1% |
| Change in working capital | $569.67K | $32.93K | $473.10K | -$78.69K | +1,630.1% |
| Operating cash flow | -$22.78M | -$10.25M | -$4.16M | -$1.06M | -122.3% |
| Investing cash flow | -$4.62M | $0 | — | — | — |
| Financing cash flow | $31.94M | $12.69M | $5.61M | $1.25M | +151.6% |
| Free cash flow | -$22.78M | -$10.25M | -$4.16M | -$1.06M | -122.3% |
| End cash position | $8.71M | $4.16M | $1.72M | $267.65K | +109.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $2.70M | $2.59M | $10.40M | $1.44M | $2.01M | +4.4% |
| Selling, general & admin | $5.89M | $5.20M | $5.02M | $4.58M | $3.12M | +13.3% |
| Total operating expense | $8.60M | $7.79M | $15.43M | $6.02M | $5.13M | +10.4% |
| Operating income | -$8.60M | -$7.79M | -$15.43M | -$6.02M | -$5.13M | -10.4% |
| Net interest income | -$318.15K | -$272.82K | $11.57K | $40.00K | $23.87K | -16.6% |
| Pre-tax income | -$9.04M | -$8.18M | -$15.98M | -$6.18M | -$5.10M | -10.5% |
| Net income | -$9.04M | -$8.18M | -$15.98M | -$6.18M | -$5.10M | -10.5% |
| Net income to common | -$9.04M | -$20.02M | -$15.98M | -$6.18M | -$5.10M | +54.8% |
| EBIT | -$8.67M | -$7.79M | -$15.43M | -$6.02M | -$5.10M | -11.3% |
| EBITDA | -$8.67M | -$7.79M | -$15.43M | -$6.02M | -$5.10M | -11.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.37M | $8.71M | $8.66M | $9.67M | $3.98M | -26.9% |
| Cash & short-term investments | $6.37M | $8.71M | $8.66M | $9.67M | $3.98M | -26.9% |
| Total current assets | $7.28M | $9.89M | $9.78M | $11.00M | $5.09M | -26.4% |
| Property, plant & equipment | $144.33K | $170.73K | $196.25K | $221.00K | $245.09K | -15.5% |
| Total assets | $7.43M | $10.06M | $9.98M | $11.93M | $5.66M | -26.2% |
| Total current liabilities | $5.95M | $9.94M | $10.66M | $8.54M | $3.34M | -40.1% |
| Current debt | $2.34M | $5.25M | $6.79M | $4.70M | — | -55.3% |
| Long-term debt | $21.04K | $25.86K | $29.46K | — | — | -18.6% |
| Total debt | $2.53M | $5.48M | $7.05M | $4.97M | $294.69K | -53.7% |
| Total liabilities | $6.00M | $10.02M | $10.78M | $8.69M | $3.51M | -40.2% |
| Retained earnings | -$73.39M | -$64.35M | -$56.16M | -$40.18M | -$34.01M | -14.1% |
| Shareholder equity | $1.33M | -$67.55K | -$910.13K | $3.25M | $2.15M | +2,063.0% |
| Working capital | $1.33M | -$47.42K | -$876.49K | $2.45M | $1.75M | +2,902.3% |
| Net tangible assets | $1.33M | -$67.55K | -$910.13K | $3.25M | $2.15M | +2,063.0% |
| Shares issued | 40.00M | 25.18M | 20.97M | 15.94M | 13.42M | +58.9% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$9.04M | -$8.18M | -$15.98M | -$6.18M | -$5.10M | -10.5% |
| Stock-based compensation | $599.31K | $429.71K | $852.76K | $117.45K | $112.28K | +39.5% |
| Change in working capital | -$1.06M | $626.57K | -$1.34M | $253.99K | $1.03M | -269.1% |
| Operating cash flow | -$8.97M | -$6.61M | -$6.76M | -$5.47M | -$3.94M | -35.7% |
| Investing cash flow | — | $0 | — | — | — | — |
| Financing cash flow | $6.83M | $6.65M | $10.37M | $11.16M | $3.76M | +2.6% |
| Free cash flow | -$8.97M | -$6.61M | -$6.76M | -$5.47M | -$3.94M | -35.7% |
| End cash position | $6.37M | $8.71M | $8.66M | $9.67M | $3.98M | -26.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
—
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
—
Peak to trough
Max drawdown 5Y
—
Peak to trough
ATR 14
—
Average true range
Beta (reported)
—
5Y monthly, from filing
Headlines
Medicus Pharma advances pipeline during Q2 with key milestones
Proactive · 12d ago
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ACCESS Newswire · 12d ago
Medicus Pharma CMO to lead Antev's Teverelix clinical programme
Proactive · 22d ago
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
GlobeNewswire · 22d ago
Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
Proactive · 24d ago
Medicus Pharma receives UAE authorization for Phase 2a endometriosis study of Teverelix
Proactive · 25d ago
Medicus Pharma Gets UAE Approval to Begin Phase 2 Endometriosis Drug trial
MT Newswires · 25d ago
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
GlobeNewswire · 25d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.